Please login to the form below
cancer treatment
This page shows the latest cancer treatment news and features for those working in and with pharma, biotech and healthcare.
Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
The treatment is already approved in the US for three disease states of prostate cancer. ... However, some patients remain at a higher risk for BCR following primary treatment, which may result in metastases.
Latest news
-
Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation
Moderna and Merck – known as MSD outside the US and Canada – have said their investigational personalised mRNA cancer vaccine, in combination with Merck’s Keytruda, has been given breakthrough therapy designation ... mRNA-4157/V940 in combination
-
AstraZeneca and MSD report final overall survival results from prostate cancer study
The combination treatment increased the current patient survival rate by over seven months. ... The combination treatment is already under priority review by the US Food and Drug Administration, based on earlier results from PROpel that demonstrated a
-
BMS, Exelixis and Ipsen report three-year results for combination treatment in kidney cancer
showed sustained survival and response rate benefits with the combination treatment versus Pfizer’s sunitinib. ... of the Cabometyx and Opdivo combination regimen as a first-line option for patients with advanced kidney cancer.”.
-
ICR calls for improved biomarker cancer tests to help personalise treatment
Each cancer has a unique pattern of biomarkers that can affect how effective treatments are. ... Each patient’s cancer has a unique pattern of biomarkers that can affect how certain treatments work.
-
World Cancer Day: encouraging men to put their health first
International World Cancer Day on 4 February raises awareness of cancer and encourages prevention, detection and treatment. ... Prostate cancer is treatable, with research suggesting that treatment at stages one and two has a near 100% survival rate,
More from news
Approximately 4 fully matching, plus 1,131 partially matching documents found.
Latest Intelligence
-
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment. ... When the technology was new, these antibodies were used predominantly in the treatment of cancer.
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Global disparities in access to cancer services – from prevention, diagnosis, treatment and management, all the way through to end-of-life care – silently shape who gets to benefit from breakthrough innovations. ... Hard times. According to WHO,
-
Putting the ovation into innovation: trends from ESMO
But it showed enough to confirm that these are exciting times in cancer research. ... The real value of real-world evidence in advanced breast cancer. Real-world evidence (RWE) is playing an ever- increasing role in treatment decision-making, in all
-
Improving outcomes in oncology – patient-centricity and mental health
Currently, a stigma of these conditions and a lack of understanding often lead to poor treatment outcomes. ... Patients want information on their health, and treatment that cannot always be given in appointments.
-
Building meaningful customer engagement through data-driven digital insights
There are several long-awaited new treatments emerging for pancreatic cancer. When we did a study of HCP views on pancreatic cancer diagnosis and treatment, we saw a real passion among ... has been a key driver of the online HCP conversation around
More from intelligence
Approximately 0 fully matching, plus 80 partially matching documents found.
Latest appointments
-
Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics
treatment of patients with cancer.”.
-
Bicycle Therapeutics appoints former Pfizer VP Maria Koehler
Dr Kevin Lee, chief executive officer at Bicycle Therapeutics, said: “As chief medical officer, Maria will play a pivotal role in furthering our mission to transform the treatment regimens for cancer ... She said: “This is a tremendous opportunity
-
Rainer Boehm and Hervé Hoppenot join Cellectics board
Through its work in developing CAR-T immunotherapies, Cellectis has an opportunity to make a significant contribution to the treatment of cancer.
-
IGEM Therapeutics appoints Dr Tim Wilson as CEO
I look forward to leading the company as we create important new therapies for the treatment of cancer.”.
-
Stephen Eck joins Aravive Biologics
I look forward to helping Aravive realise the full potential that I believe Gas6/AXL inhibition can bring to the treatment of cancer.”. ... to Houston’s M.D Anderson Cancer Centre as a member of the Advisory Board for their oncology Moonshot Programme
More from appointments
Approximately 0 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. ... These medicines underpin everyday life-saving
-
Precision versus personalised medicine
The emergence of drugs with higher selectivity or specificity to pharmacological targets has altered the landscape of cancer therapy, and modern medicine as a whole. ... The word ‘personalised’ implies that treatment is uniquely tailored to be
-
Leveraging KOL insights to succeed in a data-driven world
For example, a well-respected oncology specialist discussing the subject of breast cancer in an online forum, would be a strong KOL candidate for a company focused on breast cancer research ... and treatment.
-
The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments? ... Why does it matter? The use of immunotherapy as a cancer treatment is rapidly expanding, so it is important that patients understand basic
-
Pharmacogenomics supports and new era of precision medicine
Genetic testing is already being used in some areas of medicine, most notably in cancer and HIV treatment, and in both adult and pediatric populations, with doctors typically analysing one to ... It can also avoid wasting precious time and resources on
More from PMHub
Approximately 2 fully matching, plus 51 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
